Products
Patiromer was approved in the United States in 2015 and in many countries and the EU in 2017 as a powder for oral suspension (Veltassa).
Structure and properties
Patiromer is a nonabsorbable cation exchange polymer containing a calcium–sorbitol complex as a counterion. It exists as a white powder that is virtually insoluble in water. It is not metabolized.
Effects
Patiromer (ATC V03AE09) binds potassium in the lumen of the gastrointestinal tract and delivers it to fecal excretion. This reduces serum potassium levels. Patiromer is not absorbed into the body. The effects occur after 4 to 7 hours. Therefore, patiromer is not suitable for emergency treatment.
Indications
For the treatment of hyperkalemia in adults.
Dosage
According to the SmPC. The freshly prepared suspension is taken once daily.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Patiromer may bind other perorally administered drugs and therefore should be taken at least three hours apart.
Adverse effects
The most common potential adverse effects include gastrointestinal disturbances such as constipation, diarrhea, abdominal pain, flatulence, and hypomagnesemia.